Receta Cannabis España

Patient Information

Medical Cannabis in Spain —
Clinical and Legal Information

Rigorous, up-to-date guidance on the therapeutic use of Medical Cannabis in Spain, authorized clinical indications, the regulatory framework, and the specialized medical prescription process under Royal Decree 903/2025.

Legal Framework RD 903/2025
4 Authorized Indications
Certified Pharmaceutical Quality
Specialized Medical Prescription
Definition

What is Medical Cannabis?

Medical Cannabis refers to the therapeutic use of standardized cannabinoid-based preparations — primarily THC and CBD — for the clinical management of severe conditions where conventional medical therapies have proven insufficient.

This is strictly distinct from recreational cannabis. Authorized preparations in Spain are compounded exclusively within hospital pharmacies, ensuring known compositional profiles, certified pharmaceutical quality, and comprehensive product traceability.

🏥 Compounded in hospital pharmacies
🔬 Defined, reproducible composition
✅ Certified pharmaceutical quality
📋 Full batch traceability

Royal Decree 903/2025 regulates the therapeutic use of Medical Cannabis in Spain under specialized medical prescription within the National Health System (SNS), aligning Spain with the most stringent European clinical safety and pharmaceutical standards.

Medical Cannabis in Figures

A Treatment Supported by Growing Scientific Evidence

The accumulation of clinical trial evidence in recent years has driven regulation across Europe. Spain now joins this landscape with a rigorous, evidence-based legal framework.

+20
European countries regulating Medical Cannabis
4
authorized indications with Level A-B evidence in Spain
2025
year of enactment of RD 903/2025 in Spain
Authorized Indications

Which Conditions are Authorized in Spain?

RD 903/2025 establishes four core clinical indications supported by Level A-B scientific evidence. Outside of these specific diagnoses, access is strictly limited to authorized compassionate use pathways.

INDICATION 01

Multiple Sclerosis Spasticity

Moderate-to-severe spasticity refractory to standard first-line therapies such as baclofen or tizanidine.

INDICATION 02

Chemotherapy-Induced Nausea and Vomiting

Refractory to standard antiemetics, associated with highly or moderately emetogenic chemotherapy regimens.

INDICATION 03

Severe Refractory Epilepsy

Dravet syndrome or Lennox-Gastaut syndrome following therapeutic failure of two or more appropriate antiepileptic drugs.

INDICATION 04

Refractory Chronic Pain

Neuropathic or oncological pain with severity scores ≥ 4/10 and documented failure of at least two previous treatment lines.

⚠️ Compassionate Use: If your condition is not among the four approved clinical indications but is severe and lacks effective therapeutic alternatives, compassionate use access may be considered. This pathway requires formal approval by the Hospital Pharmacy and Therapeutics Committee and notification to the Spanish Agency of Medicines and Medical Devices (AEMPS).
Clinical Pathway

The Step-by-Step Prescription Process

Access to Medical Cannabis in Spain follows a standardized hospital-based protocol. Prescriptions can only be initiated by a specialist medical doctor within the National Health System (SNS) or accredited affiliated healthcare centers.

1

Comprehensive Specialist Clinical Assessment

The medical specialist conducts a thorough diagnostic anamnesis, examines previous therapeutic trials, and evaluates eligibility against authorized clinical criteria or compassionate use pathways.

2

Informed Consent and Clinical Documentation

The patient signs an informed consent document endorsed by the hospital Ethics Committee. The specialist issues a detailed clinical report detailing the medical rationale for treatment.

3

Hospital Electronic Prescription

The prescribing physician enters the electronic order through the hospital health informatics network, specifying exact cannabinoid ratios, pharmaceutical formulation, and dosing titration steps.

4

Hospital Pharmacy Validation and Compounding

The Hospital Pharmacy Service validates the medical prescription, formulates the standardized compounded preparation, and dispenses it directly to the patient alongside comprehensive storage and administration instructions.

5

Ongoing Clinical Follow-up and Pharmacovigilance

The clinical specialist schedules regular assessments to evaluate therapeutic efficacy, adjust dosage titration, and report any adverse drug reactions to the national pharmacovigilance network.

Dosage Forms

Which Formulations Are Authorized and Which Are Not?

Understanding which pharmaceutical preparations comply with current Spanish legislation is essential to avoid clinical risks and legal non-compliance.

✓ Authorized Formulations

  • Oral oils — standardized oily solutions
  • Gelatin capsules
  • Standardized extracts

✗ Unauthorized Formulations

  • Dried herbal flowers for vaporization/inhalation
  • Topical preparations
  • Edible products
Patient Safety

Contraindications You Must Know

RD 903/2025 delineates explicit medical contraindications. Your clinical specialist will evaluate each parameter prior to initiating therapy.

🚫 Absolute Contraindications

  • Pregnancy and breastfeeding
  • Active psychosis or history of psychotic disorders
  • Known hypersensitivity to cannabinoids
  • Severe hepatic impairment or decompensated cardiovascular disease
  • Patients under 18 years of age (except refractory pediatric epilepsy treated with isolated CBD)

⚠️ Relative Contraindications

  • Personal history of substance use disorder
  • Unstable cardiovascular condition
  • Age over 65 years
  • Regular operating of motor vehicles or hazardous machinery
Frequently Asked Questions

Common Questions from Patients

No. In Spain, Medical Cannabis can only be prescribed by a specialized medical doctor within the National Health System (SNS) or accredited affiliated healthcare institutions. It cannot be legally dispensed without a valid specialist prescription, nor obtained through unauthorized commercial channels.
Not during this initial regulatory phase. RD 903/2025 restricts prescribing privileges exclusively to hospital-based medical specialists within the SNS or contracted centers. Primary care physicians and non-affiliated private clinics are currently excluded, unless exceptional authorization is granted.
This is a critical regulatory issue. Spanish Traffic Law penalizes the mere analytical presence of THC in oral fluid (saliva) regardless of whether consumption is therapeutic or recreational. You must not drive during the dose-titration period. Subsequently, driving must be strictly avoided for 4 to 6 hours following THC administration. Always carry your clinical justification report and medical prescription with you.
Compassionate use facilitates access to Medical Cannabis for severe clinical conditions outside the four official indications when no other effective therapeutic alternatives exist. It requires a formal clinical request by the specialist, specialized patient informed consent, evaluation and approval by the Hospital Pharmacy and Therapeutics Committee, and formal notification to the AEMPS.
Like all active pharmacological therapies, Medical Cannabis may cause side effects. The most frequently observed include somnolence, dizziness, and mild cognitive or concentration changes. For this reason, clinical protocols mandate a gradual "start low, go slow" dose titration under continuous specialist supervision.
Yes. RD 903/2025 defines clear absolute contraindications: pregnancy and breastfeeding, active psychosis or diagnosed psychotic disorders, documented hypersensitivity to cannabinoids, severe hepatic impairment, decompensated cardiac failure, and patients under 18 years of age (with the exception of refractory pediatric epilepsy treated with isolated CBD).

Do you have questions about your clinical case?

Contact Us via WhatsApp

Our team will guide you through the regulatory process and available clinical options in Spain. With no obligation.

WhatsApp Us
Scroll to Top